Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK: ASPHF), which is developing treatments for blood cancer, has set terms for a US$170 million initial public offering.
In an SEC filing, Ascentage ( AAPG ) said it plans to offer 7.3 million American Depositary Shares, representing 29.3 million shares of common stock. While the company